This is the text extract for 2008-08 Cardiovascular Subcommittee Minutes, browse documents here.

Cardiovascular Subcommittee of PTAC meeting held 28 August 2008 (minutes for web publishing)

Cardiovascular Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and PTAC Subcommittees 2008: Note that this document is not necessarily a complete record of the Cardiovascular Subcommittee meeting; only the Minutes relating to Cardiovascular Subcommittee discussions about an application that contain a recommendation in relation to an application are published. The Cardiovascular Subcommittee may: (a) recommend that a pharmaceutical be listed by PHARMAC on the Pharmaceutical Schedule and the priority it gives to such a listing; (b) defer a final recommendation, and give reasons for the deferral (such as the supply of further information) and what is required before further review; or (c) recommend that PHARMAC decline to list a pharmaceutical on the Pharmaceutical Schedule.

Contents

1 Hydralazine and Metolazone for Discretionary Community Supply (DCS) Listings

1

1.1

Hydralazine and Metolazone for Discretionary Community Supply (DCS) Listings

The Subcommittee considered whether hydralazine tablets and metolazone tablets should be listed on the Discretionary Community Supply list.

Hydralazine 1.2 The Subcommittee noted that the Exceptional Circumstances Panel and Tauranga Hospital have requested consideration of hydralazine tablets being placed on the Discretionary Community Supply list. The Subcommittee noted that in the past 12 months, three Hospital Exceptional Circumstance applications have been approved for patients with congestive heart failure where ACE inhibitors were contraindicated, or renal impairment. The Subcommittee noted that the cost of hydralazine is approximately $30 per month. The Subcommittee noted that hydralazine tablets are not a registered medication and there are no current applications with Medsafe for its registration. The Subcommittee recommended that hydralazine tablets be listed on the Discretionary Community Supply list.

1.3

1.4 1.5 1.6

Metolazone 1.7 1.8 The Subcommittee noted that Tauranga Hospital has requested consideration of metolazone tablets being placed on the Discretionary Community Supply list. The Subcommittee noted that nine Hospital Exceptional Circumstance applications have been approved for patients with congestive heart failure, usually where renal impairment is present. The Subcommittee noted that the cost of metolazone tablets is usually between $40 and $600 per year dependent on dosing. The Subcommittee noted that metolazone tablets are not a registered medication and that there are no current applications with Medsafe for its registration. The Subcommittee recommended that metolazone tablets be listed on the Discretionary Community Supply list.

1.9 1.10 1.11